Key result
DREAMS 3G bioresorbable scaffold undergoes non-inferiority testing against XIENCE drug-eluting stent for revascularization.
Why the study?
The study was conducted to assess the non-inferiority of the DREAMS 3G bioresorbable scaffold against the XIENCE drug-eluting stent to determine the future role of bioresorbable scaffolds in revascularization therapy.
Does the DREAMS 3G bioresorbable scaffold demonstrate non-inferiority compared to the XIENCE drug-eluting stent in patients requiring revascularization therapy?
Does the DREAMS 3G bioresorbable scaffold demonstrate non-inferiority compared to the XIENCE drug-eluting stent in patients requiring revascularization therapy?
This study aims to determine the future role of magnesium-based bioresorbable scaffolds in revascularization by assessing non-inferiority against a standard drug-eluting stent.
Assessing the non-inferiority of the DREAMS 3G bioresorbable scaffold against the XIENCE drug-eluting stent in 1,859 patients to determine the future role of bioresorbable scaffolds in revascularization therapy.
No takes yet. Share an insight, caveat, or question.
Räber et al. (2024) studied this question. The DREAMS 3G bioresorbable scaffold is being assessed for non-inferiority against the XIENCE drug-eluting stent in 1,859 patients to determine its role in revascularization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: